CACNG4
ENSG00000075461
Target class
Auxiliary transport protein
Chromosome
17
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNG4
- Gene name
- Calcium voltage-gated channel auxiliary subunit gamma 4
- Gene symbol
- CACNG4
- Protein name
- Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage-gated calcium channel gamma-4 subunit) (Transmembrane AMPAR regulatory protein gamma-4) (TARP gamma-4)
- MGC11138
- MGC24983
- Gene biotype
- Protein coding
- Gene family
- Calcium channel auxiliary gamma subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 19
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 69.05
- Tissue specificity (Gini)
- 0.792
- Tissue specificity (tau)
- 0.91
- KEGG gene identifiers
- hsa:27092
- Protein interaction confidence
- 0.811143
- Protein interaction partners
- 56
- R-HSA-112308
- R-HSA-399719
- R-HSA-5576892
- R-HSA-5576893
- R-HSA-5682910
- End position
- 67033400
- Start position
- 66964707
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Vesicles
Publication evidence
- PubMed 21127204
- Tissue specificity (tau)
- 0.910311
- Expression inequality (Gini)
- 0.791596
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 69.05
- Brain - Caudate (basal ganglia)
- 55.38
- Brain - Putamen (basal ganglia)
- 46.44
- Brain - Hypothalamus
- 33.15
- Brain - Amygdala
- 32.13
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)69.05
- Brain - Caudate (basal ganglia)55.38
- Brain - Putamen (basal ganglia)46.44
- Brain - Hypothalamus33.15
- Brain - Amygdala32.13
- Brain - Anterior cingulate cortex (BA24)21.03
- Brain - Hippocampus20.73
- Brain - Cortex15.94
- Brain - Substantia nigra15.27
- Brain - Frontal Cortex (BA9)15.08
- Brain - Cerebellum13.77
- Brain - Spinal cord (cervical c-1)11.62
- Brain - Cerebellar Hemisphere10.23
- Lung9.8
- Prostate9.14
- Breast - Mammary Tissue2.95
- Stomach1.77
- Esophagus - Muscularis1.66
- Minor Salivary Gland1.26
- Cervix - Endocervix0.97
- Vagina0.94
- Colon - Sigmoid0.83
- Fallopian Tube0.75
- Testis0.74
- Skin - Not Sun Exposed (Suprapubic)0.68
And 29 more, listed on the interactive page.
Biological processes
- GO:2000311
- GO:0005886
- GO:0030666
- GO:1990454
- GO:0005246
- GO:0005515
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker